This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Example content
Adverse event reporting can be found at the bottom of the page
Prescribing information can be found at the bottom of the page.
Join us on 24 March 2026 to hear from Rhys Oakley, Chief Anti-Viral Pharmacist discussing 'COVID-19 Management: From Patient Identification to Treatment Selection' followed by a live interactive Q&A.
This promotional meeting is organised and funded by Pfizer Ltd for UK HCPs and will include reference to medicines promoted by Pfizer.
Prescribing information can be found at the bottom of the page.
Join us on 24 March 2026 to hear from Rhys Oakley, Chief Anti-Viral Pharmacist discussing 'COVID-19 Management: From Patient Identification to Treatment Selection' followed by a live interactive Q&A.
This promotional meeting is organised and funded by Pfizer Ltd for UK HCPs and will include reference to medicines promoted by Pfizer.
No Biography Available.
Paxlovid®▼(nirmatrelvir/ritonavir)
Paxlovid®▼(nirmatrelvir/ritonavir) has received has received Conditional Marketing Authorisation (CMA) in the United Kingdom for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.1
A Conditional Marketing Authorisation means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed when any relevant information of significance becomes available and at least every year and the product information will be updated as necessary.1
References:
1. PAXLOVID UK Summary of Product Characteristics. Pfizer Inc.
Adverse events should be reported. Reporting forms and information can be found at coronavirus-yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2026 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-13971. December 2025